Pfizer continues to make headlines with its COVID-19 initiatives, but the company prides itself in all of its scientific achievements and the financial muscle to back them up.
2021 marks the third edition of the Outcomes Creativity Index (OCI), a ranking of pharmaceutical companies and prescription brands according to creativity and innovation.
The pharmaceutical industry drew together in 2020 to fight the COVID-19 pandemic, and while the battle continues, pharma companies have even more going on.
Five years after bottoming out, Bristol Myers Squibb has moved to the first division of pharma companies with three of the world’s top eight drugs in its portfolio.
GSK continues to increase investment in the company pipeline, build on top-line momentum for key growth drivers, and largely complete readiness for the consumer healthcare business separation.
Five years after the company’s portfolio bottomed out, Bristol-Myers Squibb markets three of the world’s six best-selling pharma brands.
Eli Lilly, Johnson & Johnson and GlaxoSmithKline headline the second annual edition of the Outcomes Creativity Index (OCI), a ranking of pharmaceutical companies and prescription brands according to creativity and innovation. The OCI is an aggregate score-based creative achievement encompassing results from eight leading U.S. and international healthcare awards shows that are tabulated to rank the top 10 pharmaceutical companies and top 10 prescription brands.
2019 was a good year for the pharma industry, even as questions on value kept coming; but 2020 brought a pandemic that raised an “all hands on deck” attitude as well as business challenges.
The Outcomes Creativity Index (OCI) represents a ranking of pharmaceutical companies and brands according to creativity and innovation. The OCI is an aggregate score-based creative achievement representing these leading U.S. and international healthcare award shows: The Outcomes LLC/Med Ad News Manny Awards; Cannes Lions; LIA: Health & Wellness; Clio Health; The One Show; The MM&M Awards; The Global Awards; and The Creative Floor Awards.
The top pharmaceutical companies are trying to proactively tackle, through shifts in R&D strategy and other tactics, the healthcare demands of the future.